Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (521-530 of 642) with videos related to

Pageof 65
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 5, 2022
Interleukin-4 receptor alpha signaling regulates monocyte homeostasisPatrick Haider, Julia B Kral-Pointner, Manuel Salzmann, et al.
Biology|August 26, 2022
Neutrophile-Lymphocyte Ratio and Outcome in Takotsubo SyndromeDavid Zweiker, Edita Pogran, Laura Gargiulo, et al.
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
European Heart Journal|October 25, 2011
Antiplatelet agents for the treatment and prevention of atherothrombosisCarlo Patrono, Felicita Andreotti, Harald Arnesen, et al.
American Heart Journal|February 10, 2016
Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trialHolger Thiele, Steffen Desch, Jan J Piek, et al.
Lancet (London, England)|August 23, 2011
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trialGilles Montalescot, Uwe Zeymer, Johanne Silvain, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
Nature Reviews. Cardiology|July 20, 2023
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosisDiana A Gorog, Jose Luis Ferreiro, Ingo Ahrens, et al.
JAMA Cardiology|April 30, 2020
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialBrian A Bergmark, Michelle L O'Donoghue, Sabina A Murphy, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 31, 2017
Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
Pageof 65

Showing results (521-530 of 642) with videos related to

Sort By:
Pageof 65
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 5, 2022
Interleukin-4 receptor alpha signaling regulates monocyte homeostasisPatrick Haider, Julia B Kral-Pointner, Manuel Salzmann, et al.
Biology|August 26, 2022
Neutrophile-Lymphocyte Ratio and Outcome in Takotsubo SyndromeDavid Zweiker, Edita Pogran, Laura Gargiulo, et al.
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
European Heart Journal|October 25, 2011
Antiplatelet agents for the treatment and prevention of atherothrombosisCarlo Patrono, Felicita Andreotti, Harald Arnesen, et al.
American Heart Journal|February 10, 2016
Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trialHolger Thiele, Steffen Desch, Jan J Piek, et al.
Lancet (London, England)|August 23, 2011
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trialGilles Montalescot, Uwe Zeymer, Johanne Silvain, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
Nature Reviews. Cardiology|July 20, 2023
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosisDiana A Gorog, Jose Luis Ferreiro, Ingo Ahrens, et al.
JAMA Cardiology|April 30, 2020
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialBrian A Bergmark, Michelle L O'Donoghue, Sabina A Murphy, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 31, 2017
Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
Pageof 65